Skip to main content
. 2018 Feb 28;12(6):1786–1794. doi: 10.1007/s11682-018-9849-5

Table 1.

Group demographics with clinical and behavioral scores

Healthy controls preHD (A and B) preHD-A preHD-B Manifest HD
N 24 22‡ 11 11 10
Gender male/female 11/13 9/13 4/7 5/6 4/6
Age in years (at V1), mean (SD) 49.0 (8.2) 43.6 (8.7) 44.2 (5.7) 43.0 (11.2) 50.2 (9.3)
Handedness R/L 20/4 18/4 9/2 9/2 9/1
Level of education (ISCED), median (range) 4 (3) 4 (3) 4 (3) 4 (3) 4 (3)
DART-IQ, mean (SD) 105.0 (9.4) 100.5 (11.2) 101.3 (9.7) 99.6 (13.0) 101.8 (13.5)
CAG repeat length, mean (SD) n/a 42.6 (2.7) 41.3 (1.4) 43.9 (3.1)^ 42.5 (1.2)
Estimated years to onset, mean (SD) n/a 11.8 (4.7) 14.9 (4.7) 8.6 (1.8)^ n/a
Total functional capacity, mean (SD)
V1 13.0 (0.2) 12.8 (0.5) 12.7 (0.7) 12.8 (0.4) 11.0 (1.5)Φ
V2 12.9 (0.5) 12.6 (0.9) 12.7 (0.6) 12.5 (1.0) 10.3 (2.2)Φ
UHDRS-TMS, mean (SD)
V1 2.6 (2.5) 2.6 (1.5) 2.0 (1.5) 3.1 (1.2) 14.6 (7.7)Φ
V2 2.1 (1.6) 5.7 (5.1) ¥ 3.5 (2.2) 8.3 (6.1)*^ 23.0 (12.1)Φ
SDMT, mean (SD)
V1 49.4 (8.9) 50.1 (11.0) 53.5 (9.3) 46.7 (11.9) 41.2 (9.2)Φ
V2 50.9 (9.3) 50.6 (10.0) 54.7 (10.0) 46.6 (8.5)^ 39.2 (10.6)Φ
SWR, mean (SD)
V1 100.1 (13.2) 91.9 (14.2)* 95.6 (9.6) 88.3 (17.3)* 87.7 (14.7)*
V2 102.0 (15.6) 87.9 (15.7)* 91.4 (9.4) 84.4 (20.0)* 86.4 (18.6)*
BDI-II, mean (SD)
V1 4.1 (4.4) 6.4 (6.4) 4.9 (6.0) 7.9 (6.8) 10.2 (8.2)*
V2 3.9 (4.1) 5.1 (5.6) 3.2 (4.9) 6.9 (5.9) 8.2 (8.4)
Between-scan interval in months, mean (SD) 23.0 (0.8) 23.0 (0.7) 23.2 (0.6) 22.7 (0.7) 23.5 (0.7)

N number of participants, SD Standard deviation, n/a not applicable, ISCED International Standard Classification of Education, DART-IQ Dutch Adult Reading Test Intelligence Quotient, CAG Cytosine-Adenine-Guanine, UHDRS-TMS Unified Huntington’s Disease Rating Scale-Total Motor Score, SDMT Symbol Digit Modalities Test, SWR Stroop Word Reading task, BDI-II Beck Depression Inventory-II, V1 visit 1, V2 visit 2

Significance at p ≤ 0.05 level: * significantly different from controls, Φ significantly different from controls and preHD, ¥ significantly different from controls and HD, ^ significantly different from preHD-A

‡ Including five subjects progressing to the early manifest stage during the two year follow-up period